Masato Kajikawa1, Tatsuya Maruhashi2, Shinji Kishimoto3, Shogo Matsui2, Haruki Hashimoto2, Yuji Takaeko2, Farina Mohamad Yusoff3, Yasuki Kihara2, Kazuaki Chayama4, Chikara Goto5, Kensuke Noma1,3, Ayumu Nakashima1, Hirofumi Tomiyama6, Bonpei Takase7, Takahide Kohro8, Toru Suzuki9, Tomoko Ishizu10, Shinichiro Ueda11, Tsutomu Yamazaki12, Tomoo Furumoto13, Kazuomi Kario14, Teruo Inoue15, Shinji Koba16, Kentaro Watanabe17, Yasuhiko Takemoto18, Takuzo Hano19, Masataka Sata20, Yutaka Ishibashi21, Koichi Node22, Koji Maemura23, Yusuke Ohya24, Taiji Furukawa25, Hiroshi Ito26, Hisao Ikeda27, Akira Yamashina6, Yukihito Higashi1,3. 1. Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital. 2. Department of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University. 3. Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University. 4. Department of Gastroenterology and Metabolism, Institute of Biomedical and Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University. 5. Department of Physical Therapy, Hiroshima International University. 6. Department of Cardiology, Tokyo Medical University. 7. Division of Biomedical Engineering, National Defense Medical College Research Institute. 8. Department of Clinical Informatics, Jichi Medical University School of Medicine. 9. Cardiovascular Medicine, University of Leicester. 10. Cardiovascular Division, Institute of Clinical Medicine, University of Tsukuba. 11. Department of Clinical Pharmacology and Therapeutics, University of the Ryukyu School of Medicine. 12. Department of Clinical Epidemiology and Systems, Faculty of Medicine, The University of Tokyo. 13. Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine. 14. Division of Cardiovascular Medicine, Jichi Medical University School of Medicine. 15. Department of Cardiovascular Medicine, Dokkyo Medical University. 16. Department of Medicine, Division of Cardiology, Showa University School of Medicine. 17. Department of Neurology, Hematology, Metabolism, Endocrinology and Diabetology (DNHMED), Yamagata University School of Medicine. 18. Department of Internal Medicine and Cardiology, Osaka City University Graduate School of Medicine. 19. Department of Medical Education and Population-based Medicine, Postgraduate School of Medicine, Wakayama Medical University. 20. Department of Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School. 21. Department of General Medicine, Shimane University Faculty of Medicine. 22. Department of Cardiovascular and Renal Medicine, Saga University. 23. Department of Cardiovascular Medicine, Course of Medical and Dental Sciences, Graduate School of Biomedical Sciences, Nagasaki University. 24. The Third Department of Internal Medicine, University of the Ryukyus. 25. Department of Internal Medicine, Teikyo University School of Medicine. 26. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. 27. Faculty of Fukuoka Medical Technology, Teikyo University.
Abstract
BACKGROUND: Circulating triglyceride (TG) levels are a current focus as a residual risk for cardiovascular (CV) events. We evaluated the relationship between circulating TG levels and future CV events in patients with coronary artery disease (CAD) who were treated with conventional therapy. Methods and Results: We analyzed data for 652 patients who were enrolled in the FMD-J Study A. We investigated the associations between serum TG levels and first major CV events (death from CV cause, nonfatal acute coronary syndrome (ACS), nonfatal stroke, and CAD) for a 3-year follow-up period. Patients were divided into 4 groups based on serum TG level: low-normal (<100 mg/dL), high-normal (100-149 mg/dL), borderline hypertriglyceridemia (150-199 mg/dL), and moderate hypertriglyceridemia (≥200 mg/dL). During a median follow-up period of 46.6 months, 14 patients died (9 from CV causes), 16 had nonfatal ACS, 6 had nonfatal stroke, and 54 had CAD. The Kaplan-Meier curves for first major CV event among the 4 groups were significantly different (P=0.04). After adjustment for various confounders, serum TG level ≥100 mg/dL were significantly associated with an increased risk of first major CV events compared with serum TG level <100 mg/dL. CONCLUSIONS: Serum TG level may be a surrogate marker for predicting CV events in patients with CAD.
BACKGROUND: Circulating triglyceride (TG) levels are a current focus as a residual risk for cardiovascular (CV) events. We evaluated the relationship between circulating TG levels and future CV events in patients with coronary artery disease (CAD) who were treated with conventional therapy. Methods and Results: We analyzed data for 652 patients who were enrolled in the FMD-J Study A. We investigated the associations between serum TG levels and first major CV events (death from CV cause, nonfatal acute coronary syndrome (ACS), nonfatal stroke, and CAD) for a 3-year follow-up period. Patients were divided into 4 groups based on serum TG level: low-normal (<100 mg/dL), high-normal (100-149 mg/dL), borderline hypertriglyceridemia (150-199 mg/dL), and moderate hypertriglyceridemia (≥200 mg/dL). During a median follow-up period of 46.6 months, 14 patients died (9 from CV causes), 16 had nonfatal ACS, 6 had nonfatal stroke, and 54 had CAD. The Kaplan-Meier curves for first major CV event among the 4 groups were significantly different (P=0.04). After adjustment for various confounders, serum TG level ≥100 mg/dL were significantly associated with an increased risk of first major CV events compared with serum TG level <100 mg/dL. CONCLUSIONS: Serum TG level may be a surrogate marker for predicting CV events in patients with CAD.
Authors: Tsion Aberra; Eric D Peterson; Neha J Pagidipati; Hillary Mulder; Daniel M Wojdyla; Sephy Philip; Craig Granowitz; Ann Marie Navar Journal: J Clin Lipidol Date: 2020-05-06 Impact factor: 4.766